Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2012

View Archived Issues

Favorable in vitro data reported for beta-lactamase inhibitor RPX-7009

Phase III trials show ocriplasmin significantly resolves vitreomacular adhesion

Dendritic cell vaccines improve survival rate in melanoma

Dendritic cell vaccine compared to tumor cell vaccine in patients with metastatic melanoma

Astellas Pharma discloses novel VAP-1 inhibitors

Taisho Pharmaceutical presents new agents for alopecia

Chinese researchers patent new EGFR/HER2 inhibitors

New renin inhibitors discovered by Japanese and Chinese scientists

Taisho Pharmaceutical divulges novel MGAT2 inhibitors

Amarantus and Rainbow BioSciences form joint venture for NuroPro test

Cellerant obtains SBIR funding to develop CLT-009 for thrombocytopenia

AstraZeneca and Ardelyx sign licensing deal for NHE-3 inhibitor program

Encouraging follow-up data emerges from phase IIb PRX-302 study

New analysis of EAGLE study results demonstrate greater beneficial effects of BL-1020

Phase I interim results promising for ovarian cancer vaccine

First OTC HIV test now available in U.S.

Asterion patents new fusion proteins for GH disorders

FDA reclassifies clinical hold status for Proellex clinical program

Oral FluCide candidate reduces virus load in animal model

New safety information for Zofran issued in Canada

Potential predictor of sunitinib response in renal cell carcinoma identified

European Commission approves Bayer Healthcare's Flexyess

Ajinomoto to study nateglinide in combination with DPP IV inhibitor

Sanofi and Massachusetts General Hospital enter 2-year oncology collaboration

MedImmune enters immunotherapy collaboration with cancer organizations

Mitsubishi Tanabe and Kureha complete EPPIC phase III studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...